{"transactions":[{"id":4629680,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-10-05T20:03:44.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":8.42,"value":8420.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2026."}],"balance_after":61349,"source":{"system":"sec-edgar","filing":"0001628280-26-064902","document":"wk-form4_1791230621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599219/000162828026064902/wk-form4_1791230621.xml","form_type":"4"}},{"id":716073,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-06T13:21:30.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units (\"RSUs\") vest in three equal installments on the first, second and third anniversaries of July 1, 2026, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split."}],"balance_after":62349,"source":{"system":"sec-edgar","filing":"0001628280-26-047107","document":"wk-form4_1783344086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026047107/wk-form4_1783344086.xml","form_type":"4"}},{"id":806103,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance-based restricted stock units","published_at":"2026-04-17T22:49:01.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":352000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These are performance-based restricted stock units (\"PSU\") with terms as follows. The term of each PSU award runs from the grant date through the third anniversary of the grant date. Any unvested PSUs remaining after the third anniversary will be cancelled. The performance period for the award is the same three-year period. PSUs will vest on or after the first anniversary of the grant date only if the stock price meets the performance hurdle. The performance hurdle is met if the average closing price of the Company's common stock over any 60 consecutive trading days during the performance period equals two times the base price. The base price was calculated as the average closing price over the ten trading days ending on the trading day prior to the grant date and is $2.14 for this award."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These are performance-based restricted stock units (\"PSU\") with terms as follows. The term of each PSU award runs from the grant date through the third anniversary of the grant date. Any unvested PSUs remaining after the third anniversary will be cancelled. The performance period for the award is the same three-year period. PSUs will vest on or after the first anniversary of the grant date only if the stock price meets the performance hurdle. The performance hurdle is met if the average closing price of the Company's common stock over any 60 consecutive trading days during the performance period equals two times the base price. The base price was calculated as the average closing price over the ten trading days ending on the trading day prior to the grant date and is $2.14 for this award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These are performance-based restricted stock units (\"PSU\") with terms as follows. The term of each PSU award runs from the grant date through the third anniversary of the grant date. Any unvested PSUs remaining after the third anniversary will be cancelled. The performance period for the award is the same three-year period. PSUs will vest on or after the first anniversary of the grant date only if the stock price meets the performance hurdle. The performance hurdle is met if the average closing price of the Company's common stock over any 60 consecutive trading days during the performance period equals two times the base price. The base price was calculated as the average closing price over the ten trading days ending on the trading day prior to the grant date and is $2.14 for this award."}],"balance_after":352000,"derivative":{"expiration_date":"2028-05-20","underlying":"Common Stock","underlying_shares":352000},"source":{"system":"sec-edgar","filing":"0001104659-26-045046","document":"tm2612183-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465926045046/tm2612183-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2025-05-21"}},{"id":842267,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-16T22:08:43.000Z","date":"2026-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":7333,"price":0.9,"value":6599.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation."}],"balance_after":323493,"source":{"system":"sec-edgar","filing":"0001628280-26-018314","document":"wk-form4_1773698920.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026018314/wk-form4_1773698920.xml","form_type":"4"}},{"id":1029695,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-01T20:22:06.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":6926,"price":1.19,"value":8241.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024. The price reported above reflects the sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":330826,"source":{"system":"sec-edgar","filing":"0001628280-25-043430","document":"wk-form4_1759350124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828025043430/wk-form4_1759350124.xml","form_type":"4"}},{"id":1092998,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-03T17:26:18.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":6926,"price":0.82,"value":5679.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024 in multiple trades at prices ranging from $0.81 to $0.84. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":337752,"source":{"system":"sec-edgar","filing":"0001628280-25-034186","document":"wk-form4a_1751563574.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828025034186/wk-form4a_1751563574.xml","form_type":"4/A","original_submission_date":"2025-07-02"}},{"id":1096134,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-02T21:17:30.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":6926,"price":0.82,"value":5679.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024 in multiple trades at prices ranging from $0.81 to $0.84. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":337752,"source":{"system":"sec-edgar","filing":"0001628280-25-034068","document":"wk-form4_1751491044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828025034068/wk-form4_1751491044.xml","form_type":"4"}},{"id":1139321,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T22:56:20.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":308000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options vest 1/3 on the first anniversary of May 20, 2025, with the remaining vesting in equal monthly installments through May 20, 2028, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":308000,"derivative":{"exercise_price":1.07,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":308000},"source":{"system":"sec-edgar","filing":"0001104659-25-051704","document":"tm2515860-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465925051704/tm2515860-9_4seq1.xml","form_type":"4"}},{"id":1139320,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-21T22:56:20.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units vest on May 20, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":344678,"source":{"system":"sec-edgar","filing":"0001104659-25-051704","document":"tm2515860-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465925051704/tm2515860-9_4seq1.xml","form_type":"4"}},{"id":1184339,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-02T22:06:41.000Z","date":"2025-04-01","kind":"sale","planned":true,"acquired":false,"shares":6926,"price":1.08,"value":7480.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024 in multiple trades at prices ranging from $1.065 to $1.12. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":124678,"source":{"system":"sec-edgar","filing":"0001104659-25-031297","document":"tm2511323-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465925031297/tm2511323-3_4seq1.xml","form_type":"4"}},{"id":1201079,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T22:13:48.000Z","date":"2025-03-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":6101,"price":1.77,"value":10798.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation."}],"balance_after":131604,"source":{"system":"sec-edgar","filing":"0001104659-25-025172","document":"tm259684-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465925025172/tm259684-1_4seq1.xml","form_type":"4"}},{"id":1201078,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T22:13:48.000Z","date":"2025-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":7333,"price":1.7,"value":12466.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation."}],"balance_after":137705,"source":{"system":"sec-edgar","filing":"0001104659-25-025172","document":"tm259684-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465925025172/tm259684-1_4seq1.xml","form_type":"4"}},{"id":1311499,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-06T21:43:42.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":2163,"price":2.055,"value":4444.965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024."}],"balance_after":145038,"source":{"system":"sec-edgar","filing":"0001104659-25-001358","document":"tm252076-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465925001358/tm252076-1_4seq1.xml","form_type":"4"}},{"id":1395076,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-03T01:54:44.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":2163,"price":3.6852,"value":7971.0876,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024 in multiple trades at prices ranging from $3.67 to $3.69. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":147201,"source":{"system":"sec-edgar","filing":"0001104659-24-105580","document":"tm2425510-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924105580/tm2425510-1_4seq1.xml","form_type":"4"}},{"id":1570072,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-19T20:33:07.000Z","date":"2024-03-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":6101,"price":1.4,"value":8541.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation."}],"balance_after":149364,"source":{"system":"sec-edgar","filing":"0001104659-24-036181","document":"tm249266-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924036181/tm249266-2_4seq1.xml","form_type":"4"}},{"id":1575131,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-15T20:34:35.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":141560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options vest 25% on the first anniversary of March 14, 2024, with the remainder vesting in equal monthly installments through March 14, 2028, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":141560,"derivative":{"exercise_price":1.39,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":141560},"source":{"system":"sec-edgar","filing":"0001104659-24-035044","document":"tm248985-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924035044/tm248985-2_4seq1.xml","form_type":"4"}},{"id":1575130,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-15T20:34:35.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units vest in three equal installments on the first, second and third anniversaries of March 14, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":155465,"source":{"system":"sec-edgar","filing":"0001104659-24-035044","document":"tm248985-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924035044/tm248985-2_4seq1.xml","form_type":"4"}},{"id":1796872,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-25T22:03:00.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":3450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) Windtree's subsequent annual meeting of stockholders, provided that the reporting person remains in continuous service through the vesting date."}],"balance_after":3450,"derivative":{"exercise_price":1.21,"expiration_date":"2033-08-23","underlying":"Common Stock","underlying_shares":3450},"source":{"system":"sec-edgar","filing":"0001437749-23-024715","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923024715/rdgdoc.xml","form_type":"4"}},{"id":1796871,"issuer":{"id":8761,"kind":"organization","name":"WINDTREE THERAPEUTICS INC /DE/"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-08-25T22:03:00.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (RSUs), which represent a contingent right to receive the equivalent number of shares of common stock. These RSUs shall vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) Windtree's subsequent annual meeting of stockholders, provided that the reporting person remains in continuous service through the vesting date."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0001437749-23-024715","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946486/000143774923024715/rdgdoc.xml","form_type":"4"}},{"id":1943447,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-21T22:36:07.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":77105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options vest 25% on the first anniversary of March 17, 2023, with the remainder vesting in equal monthly installments through March 17, 2027, subject to the Reporting Person's continued service to the Issuer. Stock options are also subject to stockholder approval of an increase in the share reserve under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan at the 2023 annual meeting of stockholders."}],"balance_after":77105,"derivative":{"exercise_price":1.37,"expiration_date":"2033-03-17","underlying":"Common Stock","underlying_shares":77105},"source":{"system":"sec-edgar","filing":"0001104659-23-035190","document":"tm2310125-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923035190/tm2310125-1_4seq1.xml","form_type":"4"}},{"id":1943446,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-21T22:36:07.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":55465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Restricted stock units (\"RSUs\") vest in two equal installments on the first and second anniversaries of March 17, 2023, subject to the Reporting Person's continued service to the Issuer. RSUs are also subject to stockholder approval of an increase in the share reserve under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan at the 2023 annual meeting of stockholders."}],"balance_after":55465,"source":{"system":"sec-edgar","filing":"0001104659-23-035190","document":"tm2310125-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465923035190/tm2310125-1_4seq1.xml","form_type":"4"}},{"id":2215317,"issuer":{"id":7426,"kind":"organization","name":"ROCKWELL MEDICAL, INC.","symbol":"RMTI"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-05T20:37:22.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest in four equal installments on the first, second, third and fourth anniversaries of July 1, 2022."}],"balance_after":400000,"derivative":{"exercise_price":1.28,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001104659-22-077393","document":"tm2220421-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465922077393/tm2220421-2_4seq1.xml","form_type":"4"}},{"id":3137527,"issuer":{"id":37706,"kind":"organization","name":"Assertio Holdings, Inc.","symbol":"ASRT"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-23T00:56:22.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":291000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each outstanding option to purchase shares of Zyla's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time was converted into an option to purchase shares of Issuer common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Zyla equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Zyla option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The number of shares of Issuer  common stock subject to each such Parent option is equal to (1) the number of shares of Zyla common stock subject to the corresponding Zyla option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Issuer common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."}],"balance_after":291000,"derivative":{"exercise_price":0.6,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":291000},"source":{"system":"sec-edgar","filing":"0001104659-20-065546","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808665/000110465920065546/a4.xml","form_type":"4"}},{"id":3137526,"issuer":{"id":37706,"kind":"organization","name":"Assertio Holdings, Inc.","symbol":"ASRT"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-05-23T00:56:22.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":248599,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock of Assertio Holdings, Inc. (\"Issuer\") acquired at the effective time (\"Effective Time\") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Zyla Life Sciences (\"Zyla\") and the other parties thereto.  Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock.  Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit."},{"field":"shares","element":"transactionShares","label":"F3","text":"Totals exclude shares withheld by the Issuer for applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock of Assertio Holdings, Inc. (\"Issuer\") acquired at the effective time (\"Effective Time\") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Zyla Life Sciences (\"Zyla\") and the other parties thereto.  Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock.  Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Totals exclude shares withheld by the Issuer for applicable tax withholdings."}],"balance_after":248599,"source":{"system":"sec-edgar","filing":"0001104659-20-065546","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808665/000110465920065546/a4.xml","form_type":"4"}},{"id":3138682,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-21T16:33:01.000Z","date":"2020-05-20","kind":"disposition_to_issuer","acquired":false,"shares":116400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option to purchase shares of Issuer's common stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time, ceased to represent a right to acquire shares of Issuer common stock and was converted, at the Effective Time, into an option to purchase shares of Parent common stock, on the same terms and conditions (including any vesting or forfeiture provisions or repurchase rights, but taking into account any acceleration thereof provided for in the relevant Issuer equity plan or in the related award document by reason of the transactions contemplated by the Merger Agreement) as were applicable to such Issuer option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares of Parent common stock subject to each such Parent option is equal to (1) the number of shares of Issuer common stock subject to the corresponding Issuer option immediately prior to the Effective Time multiplied by (2) 2.5, rounded, if necessary, to the nearest whole share of Parent common stock, with an exercise per share (rounded to the nearest whole cent) adjusted as provided in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":116400},"source":{"system":"sec-edgar","filing":"0001104659-20-064799","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000110465920064799/a4.xml","form_type":"4"}},{"id":3138681,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-05-21T16:33:01.000Z","date":"2020-05-20","kind":"disposition_to_issuer","acquired":false,"shares":180864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock and derivative securities of Zyla Life Sciences (\"Issuer\") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Assertio Holdings, Inc. (\"Parent\"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. (\"Merger Sub\"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the \"Effective Time\") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock.  Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Includes unvested time-based and performance-based restricted stock units representing a contingent right to receive 180,864 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units.  At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock and derivative securities of Zyla Life Sciences (\"Issuer\") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the \"Merger Agreement\"), by and among Issuer, Assertio Holdings, Inc. (\"Parent\"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. (\"Merger Sub\"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the \"Effective Time\") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock.  Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Includes unvested time-based and performance-based restricted stock units representing a contingent right to receive 180,864 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units.  At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-064799","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000110465920064799/a4.xml","form_type":"4"}},{"id":3193939,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-26T18:25:00.000Z","date":"2020-03-26","kind":"exercise","acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted Stock Units convert into Common Stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"On March 26, 2019 the reporting person was granted 87,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 26, 2019 the reporting person was granted 87,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 26, 2019 the reporting person was granted 87,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001179110-20-004143","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020004143/edgar.xml","form_type":"4"}},{"id":3193938,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-26T18:25:00.000Z","date":"2020-03-26","kind":"exercise","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted Stock Units convert into Common Stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F4","text":"On March 26, 2019 the reporting person was granted 33,000 time-based restricted stock units that were eligible to vest on the first anniversary of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 26, 2019 the reporting person was granted 33,000 time-based restricted stock units that were eligible to vest on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 26, 2019 the reporting person was granted 33,000 time-based restricted stock units that were eligible to vest on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001179110-20-004143","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020004143/edgar.xml","form_type":"4"}},{"id":3193937,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-26T18:25:00.000Z","date":"2020-03-26","kind":"tax_withholding","acquired":false,"shares":17038,"price":1.6,"value":27260.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to pay taxes applicable to vesting of restricted stock units."}],"balance_after":44962,"source":{"system":"sec-edgar","filing":"0001179110-20-004143","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020004143/edgar.xml","form_type":"4"}},{"id":3193936,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-26T18:25:00.000Z","date":"2020-03-26","kind":"exercise","acquired":true,"shares":29000,"price":1.6,"value":46400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On March 26, 2019 the reporting person was granted 87,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date."}],"balance_after":62000,"source":{"system":"sec-edgar","filing":"0001179110-20-004143","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020004143/edgar.xml","form_type":"4"}},{"id":3193935,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-26T18:25:00.000Z","date":"2020-03-26","kind":"exercise","acquired":true,"shares":33000,"price":1.6,"value":52800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On March 26, 2019 the reporting person was granted 33,000 time-based restricted stock units that were eligible to vest on the first anniversary of the grant date."}],"balance_after":33000,"source":{"system":"sec-edgar","filing":"0001179110-20-004143","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020004143/edgar.xml","form_type":"4"}},{"id":3224181,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-05T20:46:09.000Z","date":"2020-03-04","kind":"grant","acquired":true,"shares":116400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents non-qualified stock option, 1/3 of which vests on the first anniversary of the grant date and 1/36 of which vests each month thereafter until the option is 100% vested."}],"balance_after":116400,"derivative":{"exercise_price":1.5,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":116400},"source":{"system":"sec-edgar","filing":"0001179110-20-003206","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020003206/edgar.xml","form_type":"4"}},{"id":3224180,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-05T20:46:09.000Z","date":"2020-03-04","kind":"grant","acquired":true,"shares":79800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant."}],"balance_after":79800,"source":{"system":"sec-edgar","filing":"0001179110-20-003206","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020003206/edgar.xml","form_type":"4"}},{"id":3237246,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-02T20:54:10.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":32670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into Common Stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 26, 2019 the reporting person was granted 33,000 performance-based restricted stock units that were eligible to vest on March 1, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 26, 2019 the reporting person was granted 33,000 performance-based restricted stock units that were eligible to vest on March 1, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32670},"source":{"system":"sec-edgar","filing":"0001179110-20-002746","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020002746/edgar.xml","form_type":"4"}},{"id":3237245,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-02T20:54:10.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":43065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into Common Stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 26, 2019 the reporting person was granted 87,000 performance-based restricted stock units that were eligible to vest 1/2 on March 1, 2020 and 1/2 on March 1, 2021, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 26, 2019 the reporting person was granted 87,000 performance-based restricted stock units that were eligible to vest 1/2 on March 1, 2020 and 1/2 on March 1, 2021, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43065},"source":{"system":"sec-edgar","filing":"0001179110-20-002746","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020002746/edgar.xml","form_type":"4"}},{"id":3237244,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-02T20:54:10.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":20812,"price":1.5,"value":31218.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to pay taxes applicable to vesting of restricted stock units."}],"balance_after":54923,"source":{"system":"sec-edgar","filing":"0001179110-20-002746","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020002746/edgar.xml","form_type":"4"}},{"id":3237243,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-02T20:54:10.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":32670,"price":1.5,"value":49005.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Performance-based restricted stock units granted on March 26, 2019 that vested based on 99% attainment of corporate goals. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately."}],"balance_after":75735,"source":{"system":"sec-edgar","filing":"0001179110-20-002746","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020002746/edgar.xml","form_type":"4"}},{"id":3237242,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-02T20:54:10.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":43065,"price":1.5,"value":64597.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Performance-based restricted stock units granted on March 26, 2019 that vested based on 99% attainment of corporate goals. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately."}],"balance_after":43065,"source":{"system":"sec-edgar","filing":"0001179110-20-002746","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911020002746/edgar.xml","form_type":"4"}},{"id":3574893,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-03-28T16:01:04.000Z","date":"2019-03-26","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units, which vest 100% on the first anniversary of the date of grant."}],"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001179110-19-004350","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019004350/edgar.xml","form_type":"4"}},{"id":3574892,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-03-28T16:01:04.000Z","date":"2019-03-26","kind":"grant","acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant."}],"balance_after":87000,"source":{"system":"sec-edgar","filing":"0001179110-19-004350","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019004350/edgar.xml","form_type":"4"}},{"id":3676741,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T18:32:04.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":2.38,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-19-001247","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019001247/edgar.xml","form_type":"4"}},{"id":3676740,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T18:32:04.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":8.11,"expiration_date":"2026-12-06","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-19-001247","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019001247/edgar.xml","form_type":"4"}},{"id":3676739,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T18:32:04.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":115000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":8.59,"expiration_date":"2025-11-20","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001179110-19-001247","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019001247/edgar.xml","form_type":"4"}},{"id":3676738,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T18:32:04.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":5.25,"expiration_date":"2024-12-04","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001179110-19-001247","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019001247/edgar.xml","form_type":"4"}},{"id":3676737,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-02-04T18:32:04.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Consists of Restricted Stock Units granted on March 6, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-19-001247","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019001247/edgar.xml","form_type":"4"}},{"id":3676736,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-02-04T18:32:04.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":237080,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 225,000 shares of Restricted Stock granted on June 13, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-19-001247","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911019001247/edgar.xml","form_type":"4"}},{"id":3892041,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-06-15T17:31:53.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock, 100% of which vests on the first anniversary of the date of grant."}],"balance_after":317080,"source":{"system":"sec-edgar","filing":"0001179110-18-008654","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911018008654/edgar.xml","form_type":"4"}},{"id":4004870,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-03-08T16:46:30.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, which vest in four equal annual installments beginning on the first anniversary of the date of grant, subject to acceleration of vesting based upon the percentage achievement of 2018 corporate goals attained. If there is 75% or greater achievement of 2018 corporate goals, 100% of the RSUs will vest on the first anniversary of the grant date and if there is less than 75% achievement of 2018 corporate goals, the RSUs will remain subject to the time-based vesting schedule."}],"balance_after":92080,"source":{"system":"sec-edgar","filing":"0001179110-18-003878","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911018003878/edgar.xml","form_type":"4"}},{"id":4193671,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-10-03T17:03:29.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":8700,"price":1.29,"value":11223.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12080,"source":{"system":"sec-edgar","filing":"0001179110-17-012991","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017012991/edgar.xml","form_type":"4"}},{"id":4263251,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-07-05T18:26:20.000Z","date":"2017-06-30","kind":"sale","acquired":false,"shares":8700,"price":2.39,"value":20793.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.34 to $2.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20780,"source":{"system":"sec-edgar","filing":"0001179110-17-010067","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017010067/edgar.xml","form_type":"4"}},{"id":4285035,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-12T16:40:02.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date.   25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date.   The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date."}],"balance_after":100000,"derivative":{"exercise_price":2.38,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-17-008925","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017008925/edgar.xml","form_type":"4"}},{"id":4366476,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-03-31T19:52:52.000Z","date":"2017-03-31","kind":"sale","acquired":false,"shares":8700,"price":5.11,"value":44457.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.05 to $5.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":29480,"source":{"system":"sec-edgar","filing":"0001179110-17-005319","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017005319/edgar.xml","form_type":"4"}},{"id":4501456,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-01-04T16:55:54.000Z","date":"2016-12-30","kind":"sale","acquired":false,"shares":8700,"price":7.81,"value":67947.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.74 to $8.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":38180,"source":{"system":"sec-edgar","filing":"0001179110-17-000249","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911017000249/edgar.xml","form_type":"4"}},{"id":4528320,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-08T16:27:31.000Z","date":"2016-12-06","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to one-fourth of the underlying shares on the first anniversary of the grant date and with respect to one-forty eighth of the underlying shares each month thereafter until fully vested."}],"balance_after":100000,"derivative":{"exercise_price":8.11,"expiration_date":"2026-12-06","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-16-032590","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911016032590/edgar.xml","form_type":"4"}},{"id":4589826,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2016-10-03T17:24:08.000Z","date":"2016-09-30","kind":"sale","acquired":false,"shares":25000,"price":7.59,"value":189750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale effected pursuant to a Rule 10b5-1 trading plan. The restricted stock was originally granted on February 11, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.41 to $7.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46880,"source":{"system":"sec-edgar","filing":"0001179110-16-030195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911016030195/edgar.xml","form_type":"4"}},{"id":4589825,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":32291,"kind":"person","name":"Strobeck Mark","position":1,"cik":"0001599219","reported_name":"Strobeck Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2016-10-03T17:24:08.000Z","date":"2016-09-30","kind":"sale","acquired":false,"shares":8700,"price":7.55,"value":65685.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.41 to $7.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":71880,"source":{"system":"sec-edgar","filing":"0001179110-16-030195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586105/000117911016030195/edgar.xml","form_type":"4"}}]}